Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cubicin®
Daptomycin · 1 trial · 2 indications
Erythrocyte volume fraction means under certain conditions, after centrifugation pressing, the percentage of erythrocyte volume in the total volume of blood
percentage of patients who were primarily tested as normal ECG at baseline and changed into abnormal ECG at TOC visit in all the patients with normal ECG at baseline
| Arm | Type | Description |
|---|---|---|
| AZ drug | EXPERIMENTAL | Daptomycin |
| Comparator | ACTIVE_COMPARATOR | Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin |
| Name | Type | Description |
|---|---|---|
| Daptomycin | DRUG | 4mg/kg IV ; Q 24 hr (once every 24 hours) |
| Vancomycin | DRUG | Vancomycin - 1g per 12 hrs, for 7-14 days Or switch to Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin: \- 1 g every 6 hours or 2 g every 8 hours |
Inclusion Criteria: * Provision of inform consent * A diagnosis of of complicated skin and skin structure infection known or suspected to be due to Gram-positive bacteria * Diagnosis of bacterial skin and skin structure infection in the presence of some complicating factor, including infections inv...
Top 4 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Eli Lilly and Company | LLY | 1 | PHASE3 | Lepodisiran |
| Illumina, Inc. | ILMN | 1 | PHASE1 | 18F-mFBG for administration |
Daptomycin is being developed for the treatment of skin diseases, specifically skin infections. It is an investigational small molecule in the infectious disease therapeutic area. AstraZeneca PLC is advancing it through Phase 3 clinical development, with a completed registration study conducted in China in patients with skin infections.
Daptomycin is developed by AstraZeneca PLC, which trades under the ticker AZN. The company is responsible for the clinical development program, including the Phase 3 registration study in China that evaluated the drug in patients with skin infections.
Daptomycin is in Phase 3 clinical development. One Phase 3 trial has been completed, and no active trials are currently listed. The completed study was a randomized, active-controlled registration trial in China that enrolled 265 patients with skin infections.
Daptomycin has been studied in one completed Phase 3 trial, NCT00772447, titled China Registration Study in Patients With Skin Infections. The trial enrolled 265 adults aged 18 years and older of all sexes, was randomized and active-controlled, and was conducted in China.
Daptomycin is an investigational drug and has not been approved by the FDA for the skin infection indication described here. It remains in clinical development, with a completed Phase 3 registration study in China serving as the key trial data for this asset.